Stock Detail
TRANSITION THERAPEUTICS INC - (CANADA) ORDINARY SHARES
Biotechnology
TTHI @ Yahoo Finance | TTHI Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $1.55 | $1.60 | $-0.01 | -0.69% | 0.00 | $1.56 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $1.55 | $1.55 | 6,544 | 35.99M | 19,512.67 | 2.57 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 1.62 | 1.59 | 1.57 | 1.54 | 1.52 |
Stock Profile
Transition Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutics for various disease indications. Its lead products include ELND-005/AZD-103 for the treatment of Alzheimer's disease, and regenerative therapies E1-I.N.T. and GLP1-I.N.T. for the treatment of diabetes. ELND-005/AZD-103 completed multiple Phase I clinical studies and E1-I.N.T. completed a Phase IIa clinical trial. GLP1-I.N.T. is under preparation for Phase II clinical development. The company is also developing MS-I.E.T. for the treatment of multiple sclerosis and HCV-I.E.T. for the treatment of hepatitis C. In addition, Transition Therapeutics has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. The company has a partnership with Elan Pharma International Limited for the development and commercialization of ELND-005/AZD-103 therapeutic agent. Transition Therapeutics was founded in 1987. It was formerly known as Transition Therapeutics and Diagnostics, Inc. and changed its name to Transition Therapeutics, Inc. in 2000. The company is based in Toronto, Canada.